Income Statement
CALIDI BIOTHERAPEUTICS, INC.
CLDI
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
20.24 | 21.78 | 28.99 | 4.67 | 0.00 |
|
Research & Development
|
9.74 | 8.88 | 13.01 | - | - |
|
Selling, General & Administrative
|
10.50 | 12.90 | 15.98 | - | - |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-20.24 | -21.78 | -28.99 | -4.67 | - |
|
Non-Operating Income
|
0.19 | -0.42 | -0.21 | 8.55 | - |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
0.10 | 0.70 | 1.10 | - | - |
|
Other Non-Op Income / Expense
|
0.10 | 0.01 | 2.41 | - | - |
|
Income Before Tax
|
0.05 | 0.02 | -1.22 | 3.88 | - |
|
Income Tax Expense
|
0.02 | 0.01 | 0.02 | 0.35 | - |
|
Non-Controlling Interest
|
-0.16 | -0.07 | - | - | - |
|
Net Income
|
-20.06 | -22.21 | 87.63 | 3.53 | - |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-18.59 | -21.78 | -28.99 | -4.67 | 0.00 |
|
Earnings Per Share (Basic)
|
-5.95 | -2.97 | 1.73 | 0.18 | - |
|
Diluted EPS
|
-5.95 | -2.97 | 1.73 | 0.18 | - |
|
Weighted Average Shares
|
0.00 | 8.01 | 16.89 | 17.67 | - |
|
Diluted Weighted Avg Shares
|
0.00 | 8.01 | 16.89 | 17.67 | - |
|
Comprehensive Income
|
-19.89 | -22.12 | -29.25 | - | - |